Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (89)

I-01Nurul Azrin Abd Rahman

A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax Volunteer-Infection Study

Wednesday 09:50-11:15

I-02Mahmoud Abdelwahab

Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis

Wednesday 09:50-11:15

I-03

Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice

Wednesday 09:50-11:15

I-04Anson Abraham

Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design?

Wednesday 09:50-11:15

I-05Ahmad Abuhelwa

Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression

Wednesday 09:50-11:15

I-06Ahmed Aliyu Abulfathi

External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package

Wednesday 09:50-11:15

I-07Oliver Ackaert

Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects

Wednesday 09:50-11:15

I-08Bambang Adiwijaya

Component score models of HAMD were more predictive than total score models

Wednesday 09:50-11:15

I-09Jae Eun Ahn

Longitudinal Model-Based Meta-Analysis for Liver Biomarkers and Biopsy Endpoints in Patients with Non-Alcoholic Fatty Liver Disease

Wednesday 09:50-11:15

I-10Maurice Ahsman

A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy

Wednesday 09:50-11:15

I-11Marie Alexandre

Modeling viral rebound in HIV therapeutic vaccine studies

Wednesday 09:50-11:15

I-12Joachim Almquist

Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation

Wednesday 09:50-11:15

I-13Jokha AL-Qassabi

Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment

Wednesday 09:50-11:15

I-14Hesham Al-Sallami

The use of a Bayesian dosing tool to optimise enoxaparin treatment: a pilot clinical study

Wednesday 09:50-11:15

I-15Vincent Aranzana-Climent

Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii

Wednesday 09:50-11:15

I-16Million Arefayene

Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of anti-avß6 integrin Antibody (BG00011)

Wednesday 09:50-11:15

I-17Leticia Arrington

An R package for Automated Generation of Item Response Theory Model NONMEM Control File

Wednesday 09:50-11:15

I-18Usman Arshad

A semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients

Wednesday 09:50-11:15

I-19Muhammad Waqar Ashraf

Mechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers

Wednesday 09:50-11:15

I-20Magnus Åstrand

nonmem2R: An R-package for Visual Predictive Checks and Goodness-of-fit Plots

Wednesday 09:50-11:15

I-21Ioanna Athanasiadou

Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis

Wednesday 09:50-11:15

I-22Linda Aulin

Physiologically-based pharmacokinetic model to predict lung distribution of anti-infective agents

Wednesday 09:50-11:15

I-23Rami Ayoun Alsoud

Simultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy

Wednesday 09:50-11:15

I-24Geraldine Celliere

Straightforward dose adaptation simulations with Simulx, the simulator of the MonolixSuite

Wednesday 09:50-11:15

I-25LE Ba Hai

Population pharmacokinetic model of sorafenib and application to a case report

Wednesday 09:50-11:15

I-26Junjie Ding

Pharmacometric drug adherence approach and its application in a clinical setting

Wednesday 09:50-11:15

I-27Vanessa Baier

Assessing the cholestatic potential of drugs using a physiology-based model of the bile acid metabolism

Wednesday 09:50-11:15

I-28Pavel Balazki

A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologically-based pharmacokinetics models.

Wednesday 09:50-11:15

I-29Violeta Balbas-Martinez

Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn’s Disease

Wednesday 09:50-11:15

I-30Irina Baltcheva

ggPMX: an open-source R package for pharmacometric model diagnostic plots

Wednesday 09:50-11:15

I-31Maddlie Bardol

Population pharmacokinetics of fentanyl in very preterm infants

Wednesday 09:50-11:15

I-32Christian Bartels

Getting a better description of treatment effects for time to event data using PKPD modelling

Wednesday 09:50-11:15

I-33Roberta Bartolucci

Optimal design of paediatric clinical trials: the Macitentan case study

Wednesday 09:50-11:15

I-34Carla Bastida Fernández

Assessment of tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients

Wednesday 09:50-11:15

I-35Francesco Bellanti

Application of Model-Based Meta-Analysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of anti-asthmatic drugs

Wednesday 09:50-11:15

I-36Amina Bensalem

Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis

Wednesday 09:50-11:15

I-37Linnea Bergenholm

Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3-conjugated antisense oligonucleotide using sparse monkey data

Wednesday 09:50-11:15

I-38Aliénor Bergès

Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case

Wednesday 09:50-11:15

I-39Martin Bergstrand

Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling

Wednesday 09:50-11:15

I-40Jan Berkhout

Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia

Wednesday 09:50-11:15

I-41Julie Bertrand

Model-based approach for group sequential and adaptive designs in parallel and cross-over bioequivalence studies

Wednesday 09:50-11:15

I-42Robert Bies

On the Multilemma of reproducibility: Stochastic or Deterministic or Stochastic and Deterministic

Wednesday 09:50-11:15

I-43Bruno Bieth

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer

Wednesday 09:50-11:15

I-44Roberto Bizzotto

Conditional linear mixed-effect modelling of HbA1c and fasting glucose in diabetic patients shows that progression rates for the two variables are different: an IMI DIRECT study

Wednesday 09:50-11:15

I-45Irina Bondareva

Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data

Wednesday 09:50-11:15

I-46Guillaume Bonnefois

A new computational approach to match control subjects to renal impaired patients in pharmacokinetic studies

Wednesday 09:50-11:15

I-47Elisa Borella

Development of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia

Wednesday 09:50-11:15

I-48Agnieszka Borsuk-De Moor

The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits

Wednesday 09:50-11:15

I-49Thomas Bouillon

Model predictive control with Bayesian updates (MPC) is more robust to model misspecification, compared to standard Bayesian control (sEBE) for Therapeutic Drug Management (TDM). Investigation in a cohort of 315 patients receiving tacrolimus during the first 14d after renal transplantation.

Wednesday 09:50-11:15

I-50Marion Bouillon-Pichault

Model-based meta-analysis of efficacy and safety of anti-PD1 compounds in melanoma

Wednesday 09:50-11:15

I-51Muriel Boulton

What is the proportion of abiraterone acetate effect on radiographic Progression-Free-Survival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castration-resistant prostate cancer (mCRPC)?

Wednesday 09:50-11:15

I-52

Model based support to biosimilarity assessment planning – A case study of pegfilgrastim

Wednesday 09:50-11:15

I-53Astrid Broeker

Parameter uncertainty in small datasets – evaluation approaches at their limit

Wednesday 09:50-11:15

I-54Vincent Buchheit

Data scientists for improving efficiency and quality of quantitative clinical pharmacology analyses

Wednesday 09:50-11:15

I-55Núria Buil Bruna

Can monocyte counts predict future drug-induced neutropenia toxicities?

Wednesday 09:50-11:15

I-56David Busse

Analysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling

Wednesday 09:50-11:15

I-57Antonio Cabal

Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery

Wednesday 09:50-11:15

I-58Unai Caballero

Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris

Wednesday 09:50-11:15

I-59Elisa Calvier

Alirocumab population pharmacokinetics in Chinese patients using priors

Wednesday 09:50-11:15

I-60Tim Cardilin

Tumor Static Exposure for anticancer combinations in early drug discovery

Wednesday 09:50-11:15

I-61Fernando Carreño

Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia

Wednesday 09:50-11:15

I-62Jantine Brussee

Model-based dose optimization of ivermectin to achieve equivalent exposure coverage in children and adults

Wednesday 09:50-11:15

I-63Blesson Chacko

Why patients may not benefit from effective oncology drugs

Wednesday 09:50-11:15

I-64Dong Woo Chae

Predictive model of postoperative nausea and vomiting in patients treated with Fentanyl-based intravenous patient controlled analgesia

Wednesday 09:50-11:15

I-65Anne Chain

A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia

Wednesday 09:50-11:15

I-66Anna Chan Kwong

Bridging studies: handling covariates models using the Prior approach

Wednesday 09:50-11:15

I-67Christophe Chassagnole

A precision dosing application for docetaxel in metastatic prostate cancer

Wednesday 09:50-11:15

I-68Estelle Chasseloup

Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part II – control of the type I error with real placebo data

Wednesday 09:50-11:15

I-69Jonathan Chauvin

Novel user-friendly applications for dose individualization of sunitinib and imatinib

Wednesday 09:50-11:15

I-70Alexia Chauzy

Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria

Wednesday 09:50-11:15

I-71Viji Chelliah

Mechanistic models of cancer-immune cycle and immunotherapies

Wednesday 09:50-11:15

I-72Lu Chen

Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis

Wednesday 09:50-11:15

I-73Maxwell Chirehwa

Population pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients

Wednesday 09:50-11:15

I-74Siri Kalyan Chirumamilla

Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients

Wednesday 09:50-11:15

I-75Palang Chotsiri

Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity

Wednesday 09:50-11:15

I-76Emmanuelle Comets

Conditional non-parametric bootstrap for non-linear mixed effect models

Wednesday 09:50-11:15

I-77Valerie Cosson

Target-mediated drug disposition model of RG6206 (RO7239361), an anti-myostatin adnectin-IgG1-Fc-fusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy

Wednesday 09:50-11:15

I-78Perrine Courlet

Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV.

Wednesday 09:50-11:15

I-79Sinziana Cristea

Untangling maturation functions for kidney transporters using a combined population pharmacokinetics and physiology-based pharmacokinetics approach

Wednesday 09:50-11:15

I-80Salvatore D'Agate

Population Pharmacokinetics and Effect of Variable Renal Function on the Exposure to Aciclovir in Term and Pre-term Neonates

Wednesday 09:50-11:15

I-81Kim Dao

Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells

Wednesday 09:50-11:15

I-82Mailys De Sousa Mendes

Transporter inhibition: modelling in-vitro Transwell assays

Wednesday 09:50-11:15

I-83Eva Maria del Amo Paez

Pharmacokinetics after intravitreal injection of a new anti-angiogenic therapeutic compound in rabbit eyes

Wednesday 09:50-11:15

I-84Francesca Del Bene

Intratympanic drug administration: a challenge for PK modelling

Wednesday 09:50-11:15

I-85Laurence Del Frari

Population modelling and simulations of binimetinib pharmacokinetics in subjects with hepatic impairment to explore optimal dosing regimen using total and unbound binimetinib exposures

Wednesday 09:50-11:15

I-86Oleg Demin Jr

Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling

Wednesday 09:50-11:15

I-87Laure Deyme

Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue

Wednesday 09:50-11:15

I-88Sofie Dhaese

The use of optimal experimental design to inform a clinical trial on non-linearity of piperacillin clearance in critically ill patients.

Wednesday 09:50-11:15

I-89Richard Dimelow

PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously

Wednesday 09:50-11:15